TY - CHAP
T1 - Alzheimer's Disease. Clinical Features, Neuropathological and Biochemical Abnormalities, Genetics, Models, and Experimental Therapeutics
AU - Price, Donald L.
AU - Borchelt, David R.
AU - Wong, Philip C.
N1 - Funding Information:
The authors wish to thank the many colleagues who have worked at JHMI as well as those at other institutions for their contributions to some of the original work cited in this review and for their helpful discussions. Aspects of this work were supported by grants from the U.S. Public Health Service (AG05146) as well as the Metropolitan Life Foundation, Adler Foundation, CART Foundation, and Bristol-Myers Squibb Foundation.
PY - 2005
Y1 - 2005
N2 - This chapter focuses on Alzheimer's disease (AD), the most common age-related dementia, and on the value of experimental models for understanding disease mechanisms and for insights into experimental therapeutics. Characteristic intracellular and extracellular protein aggregates, implicated in pathogenic processes, are critical elements of this pathology. Targeting of genes encoding proteins thought to be implicated in disease pathways has provided new understanding of the roles of specific gene products in AD and the potential of these proteins as therapeutic targets. The value of these targets for new treatment strategies is being tested in model systems and, once safety and efficacy are assured, in human trials. This chapter illustrates the clinical, pathological, biochemical, and genetic features of the human illness. Furthermore, it discusses selected aspects namely, the biology of proteins implicated in pathogenesis of disease, the value of genetically engineered models, the identification of new therapeutic targets, and experimental treatments in models.
AB - This chapter focuses on Alzheimer's disease (AD), the most common age-related dementia, and on the value of experimental models for understanding disease mechanisms and for insights into experimental therapeutics. Characteristic intracellular and extracellular protein aggregates, implicated in pathogenic processes, are critical elements of this pathology. Targeting of genes encoding proteins thought to be implicated in disease pathways has provided new understanding of the roles of specific gene products in AD and the potential of these proteins as therapeutic targets. The value of these targets for new treatment strategies is being tested in model systems and, once safety and efficacy are assured, in human trials. This chapter illustrates the clinical, pathological, biochemical, and genetic features of the human illness. Furthermore, it discusses selected aspects namely, the biology of proteins implicated in pathogenesis of disease, the value of genetically engineered models, the identification of new therapeutic targets, and experimental treatments in models.
UR - http://www.scopus.com/inward/record.url?scp=84882531124&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84882531124&partnerID=8YFLogxK
U2 - 10.1016/B978-012738903-5/50028-X
DO - 10.1016/B978-012738903-5/50028-X
M3 - Chapter
AN - SCOPUS:84882531124
SN - 9780127389035
SP - 445
EP - 458
BT - From NEUROSCIENCE To NEUROLOGY
PB - Elsevier Inc.
ER -